---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-106820"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2024-09-16T23:59:59+00:00"
generated_at: "2026-05-31T04:38:04.120752+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Dianthus Therapeutics appoints Steven Romano, M.D. to Board of Directors

## Summary
- Appointed Steven Romano, M.D. as Class III director and member of Science & Technology Committee, effective September 16, 2024.
- Initial option grant of 22,000 shares vesting one-third annually over three years.
- Annual cash compensation: $40,000 for board service plus $5,000 for S&T Committee, paid quarterly.
- Dr. Romano will also be eligible for future annual equity grants under the Non-Employee Director Compensation Policy.

## SEC filing metadata
- accession: 0000950170-24-106820
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2024-09-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017024106820/0000950170-24-106820-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017024106820/dnth-20240916.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-106820
- JSON: https://secwatch.observer/filing/0000950170-24-106820.json
- Plain text: https://secwatch.observer/filing/0000950170-24-106820.txt

## Key facts
- Executive change
  Steven Romano, M.D. was appointed as Class III director at Dianthus Therapeutics, Inc. /DE/.
  - Action: appointed
  - Role: Class III director
  source text: On September 16, 2024, the Board of Directors (the “Board”) of Dianthus Therapeutics, Inc. (the “Company”) appointed Steven Romano, M.D. as a Class III director of the Company and as a member of the Science and Technology Committee of the Board (the “S&T Committee”), effective immediately.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1690585/000095017024106820/0000950170-24-106820-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.